3 Growth Companies With High Insider Ownership Expecting 104% Earnings Growth

En este artículo:

As global markets navigate a choppy start to the year, characterized by inflation concerns and political uncertainties, investors are closely watching for signs of stability amid fluctuating indices. In such an environment, growth companies with high insider ownership can offer unique insights into potential earnings expansion, as insiders often have a vested interest in the company's long-term success.

Top 10 Growth Companies With High Insider Ownership

Name

Insider Ownership

Earnings Growth

Duc Giang Chemicals Group (HOSE:DGC)

31.4%

23.8%

Archean Chemical Industries (NSEI:ACI)

22.9%

41.2%

Kirloskar Pneumatic (BSE:505283)

30.3%

26.3%

Clinuvel Pharmaceuticals (ASX:CUV)

10.4%

26.2%

People & Technology (KOSDAQ:A137400)

16.4%

37.3%

Medley (TSE:4480)

34%

27.2%

Brightstar Resources (ASX:BTR)

16.2%

84.3%

Plenti Group (ASX:PLT)

12.8%

120.1%

Fulin Precision (SZSE:300432)

13.6%

66.7%

Findi (ASX:FND)

34.8%

112.9%

Click here to see the full list of 1455 stocks from our Fast Growing Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

DPC Dash

Simply Wall St Growth Rating: ★★★★★☆

Overview: DPC Dash Ltd, along with its subsidiaries, operates a chain of fast-food restaurants in the People’s Republic of China and has a market cap of HK$9.73 billion.

Operations: The company generates revenue of CN¥3.72 billion from its chain of fast-food restaurants in the People’s Republic of China.

Insider Ownership: 38.1%

Earnings Growth Forecast: 104.8% p.a.

DPC Dash, Domino's Pizza's master franchisee in China, has shown significant growth with the opening of its 1,000th store and a nearly tenfold expansion since 2017. Despite recent board changes, the company maintains strong insider ownership. It achieved double-digit revenue growth in 2024, reaching RMB 2.04 billion for H1 and reported its first positive net profit. Forecasts indicate continued robust revenue growth at 24.9% annually over three years, outpacing the Hong Kong market average.

SEHK:1405 Earnings and Revenue Growth as at Jan 2025
SEHK:1405 Earnings and Revenue Growth as at Jan 2025

Gan & Lee Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: Gan & Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog APIs and injections in China with a market cap of CN¥25.20 billion.

Operations: The company generates revenue of CN¥2.95 billion from the development, production, and sales of insulin and related products.